NORD-STAR substudy of coagulation and fibrinolytic parameters: 〽️Impairement in eRA ⚡️Biologic parameters restored by ttmt. Effect seemed ▶️ with Biologic vs. MTX + GCs ❕No adjustment on disease activity #OP0059 #EULAR2022 @RheumNow https://t.co/CJHldOimBn

🚨 Depression = major comorbidity! DANBIO register 10000+ patients: ❗️10% prescription antidepressants💊 ❗️Cumulative mortality ⬆️ w/ OR>6 ❗️Particularly in age group <55 #OP0067 #EULAR2022 @RheumNow https://t.co/le8VWBFjPK

Silverio-Antonio et al. Predictors of ILD development in MCTD. Older age at diagnosis (OR 1.1) and lymphadenopathy at presentation (OR 19.65)! predictors @RheumNow #EULAR2022 POS0901 https://t.co/IJ8Vcaga8o

Chen et al. Adalimumab biosimilar (Amgevita) in JIA. Not a switch study, these are initiators. Expected efficacy and safety outcomes of adalimumab seen here. Good to see more of these data to try and break down the last barriers to biosimilars @RheumNow #EULAR2022 POS1294 https://t.co/yoM2dIXLDQ

Do biomarkers correlate with change in disease activity in #PsA? Esp IL17F not so much other IL17s, and IL6, IL23. Ian McInnes ? next steps 🤷‍♀️ to separate responder and non responder @RheumNow #EULAR2022 OP0024 https://t.co/JMmENRa80t

Norwich regimen of steroids for GCA @cmukhtyar et al. Bespoke regime starting at 1mg/kg tapered over 100 weeks. Drug-free relapse free survival 82% at 100 weeks, 69% 150 weeks. @RheumNow #EULAR2022 POS0793 https://t.co/b5smCqCkgg

Have always been fascinated by the idea that some b/tsDMARDs might have effects on pain and fatigue beyond inflammation control. Baricitinib data in RA before, & now this from guselkumab. Substantial effect on pain beyond SJC/CRP attributable? POS1030 #EULAR2022 #IL23 @RheumNow https://t.co/fxqIGnlkwU

Proton Rahman discusses #PsA and #fatigue ⬇️ in #Guselkumab RCTs. 2/3 of fatigue was explained by pt factors - pt global and pain, skin, joints, CRP, function drove the data. Ask pt and treat what is treatable. #OP0025 @eular @RheumNow https://t.co/x4T6sPEi8o